A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review

Study Identifier
H24-962
CT.gov Identifier
NCT06503536
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dermatology - Atopic Dermatitis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    12+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants with at least one primary diagnosis of atopic dermatitis with ICD-10 code of L20.900 \[atopic dermatitis, unspecified\] or physician-confirmed atopic dermatitis documentation within the study period * Participants with at least one documented health record of upadacitinib prescription that has a primary diagnosis of atopic dermatitis within the study period * Participants with at least one atopic dermatitis severity measures (i.e., EASI) in the follow-up period including up to 6 months after the index date
    Exclusion Criteria:
    • Participants who did not fulfill the inclusion criteria will be excluded

    Protocol Summary

    Atopic Dermatitis (AD) is a common, chronic, and flaring systemic inflammatory skin disorder characterized by intensely pruritic and distressing skin eruptions. This study will assess treatment patterns, treatment outcomes, healthcare resource utilization in Chinese participants receiving Upadacitinib for Atopic Dermatitis (AD) undergoing chart review.

    Study Locations

    Location
    Status
    Location
    Huashan Hospital affiliated to Fudan University /ID# 268259
    Shanghai, Shanghai Municipality, China, 200040
    Status
    Not applicable